FYI Broadfin increased its position in Biota Pharmaceuticals...

FYI



Broadfin increased its position in Biota Pharmaceuticals (NASDAQ:BOTA) by 132% (almost 1.5 million shares), which was valued at almost $6.5 million as of Q3 end. Last month, I highlighted BOTA as a cost-cutting biopharmaceutical influenza play with an attractive valuation considering clinical catalysts on tap for 2015, and I continue to hold this view.

Broadfin Capital = Broadfin Capital is a global equity healthcare manager founded in 2005 that seeks long-term compound returns in the mid-teens through the consistent application of a value-oriented investment strategy. Led by former Galleon Group portfolio manager and Wharton grad Kevin Kotler,Broadfin manages more than $1.25 billion with positions in 78 securities